An IND submission is a critical step in drug development because it determines whether an investigational product can be tested in humans. Understanding what an IND is and meeting IND requirements early helps companies avoid regulatory delays and safety concerns […]
Biologic therapies are central to modern healthcare, enabling advanced treatments for cancer, autoimmune disorders, and rare genetic diseases. Products such as vaccines, monoclonal antibodies, and cell and gene therapies are now integral to many drug development programs. Before a biologic
What happens when a clinical trial protocol gets lost in translation? It’s dangerous, expensive, and potentially catastrophic for patient safety. Yet most biotech companies still treat biotech translation like something to outsource to the cheapest bidder at the last minute.
Launching a medical device today requires more than proving safety and performance. Commercial success depends on whether the device can be used, reimbursed, and adopted within healthcare systems. This is where medical device market access becomes critical. Market access includes
Entering the United States medical device market requires more than a technically sound product. Manufacturers must demonstrate regulatory compliance, provide complete and internally consistent documentation, and communicate clearly with the U.S. Food and Drug Administration (FDA). For most Class II
Japan is one of the world’s largest and most sophisticated medical device markets. With a rapidly aging population, rising chronic disease burden, and substantial government investment in healthcare, demand for advanced medical technologies continues to grow. In 2024, Japan’s medical
90% of B2B researchers use search engines specifically to research business purchases. And 71% start with a generic Google search. Not LinkedIn or a vendor call. If you’re not showing up in those searches, you’re simply not in the conversation.
A strong medical device regulatory strategy is essential for patient safety, product quality, and long-term market access. Regulatory authorities such as the U.S. Food and Drug Administration and the European Union Medical Device Regulation now apply stricter requirements to technical
One wrong dosage. One misunderstood side effect. One incorrectly translated consent form. Any of these mistakes can shut down a clinical trial, trigger a regulatory rejection, or harm a patient. Medical translation demands clinical knowledge, regulatory expertise, and absolute precision.
The medical device industry is inherently global. Devices are often developed in one country, manufactured in another, and sold across multiple regions, each with its own regulatory and language requirements. As of 2025, the global medical devices market is valued
Getting regulatory approval is hard. But getting paid for your drug after approval is the real battle. More than a third of drug launches fail to meet revenue forecasts in their first year, not because the science failed, but because
The European Union’s Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) have significantly increased regulatory expectations for medical device and IVD manufacturers. Beyond technical performance and clinical evidence, both regulations place strong emphasis on patient safety, usability, and
